Skip to content
NASDAQNRSN
Investor Relations

Company Profile

NeuroSense Therapeutics is a clinical-stage biopharmaceutical company, focusing on the discovery and development of targeted innovative therapeutics for neurodegenerative diseases.

NeuroSense was founded in 2017 by Alon Ben-Noon, following a chance meeting with Shay Rishoni, an ALS patient. During this meeting, Alon was inspired by Shay, who served as the CEO of a non-profit organization for ALS. Despite Shay not having a physical voice, therefore communicating via eye movement and computer software, the connection was instant. Shay detailed his activities in the ALS field, and described the efforts that are being made to solve the ALS puzzle, leading Alon to team up with world-renowned scientists and colleagues in order to research and develop an effective drug for ALS patients, bringing about the establishment of NeuroSense.

We are focused on creating combined therapeutic strategies, targeting the multiple pertinent mechanisms in these complex diseases.

Recent News
Mar 27, 2023

In vitro studies to test the effects of PrimeC on key pathways involved in ALS including TDP-43 accumulation, autophagy defects, mitochondrial dysfunction, and oxidative stress Preliminary results...

Mar 23, 2023

Biomarkers show potential efficacy PrimeC is currently being evaluated for the treatment of ALS in a Phase 2b study with topline results expected in H2 2023 Phase 2 double-blind proof-of-concept...

Mar 22, 2023

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, announced today that its annual report on Form 20-F, containing...

Investor Presentation
Board Diversity Matrix